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Purpose: Multiple commercial, open-source, and academic software tools exist for objective quan-
tification of lung density in computed tomography (CT) images. The purpose of this study was to
evaluate the intersoftware reproducibility of CT lung density measurements.
Methods: Computed tomography images from 50 participants from the COPDGeneTM cohort study
were randomly selected for analysis; n = 10 participants across each global initiative for chronic
obstructive lung disease (GOLD) grade (GOLD 0–IV). Academic-based groups (n = 4) and commer-
cial vendors (n = 4) participated anonymously to generate CT lung density measurements using their
software tools. Computed tomography total lung volume (TLV), percentage of the low attenuation
areas in the lung with Hounsfield unit (HU) values below 950HU (LAA950), and the HU value cor-
responding to the 15th percentile on the parenchymal density histogram (Perc15) were included in
the analysis. The intersoftware bias and reproducibility coefficient (RDC) was generated with and
without quality assurance (QA) for manual correction of the lung segmentation; intrasoftware bias
and RDC was also generated by repeated measurements on the same images.
Results: Intersoftware mean bias was within 0.22 mL, 0.46%, and 0.97 HU for TLV, LAA950
and Perc15, respectively. The RDC was 0.35 L, 1.2% and 1.8 HU for TLV, LAA950 and Perc15,
respectively. Intersoftware RDC remained unchanged following QA: 0.35 L, 1.2% and 1.8 HU for
TLV, LAA950 and Perc15, respectively. All software investigated had an intrasoftware RDC of 0. The
RDC was comparable for TLV, LAA950 and Perc15 measurements, respectively, for academic-based
groups/commercial vendor-based software tools: 0.39 L/0.32 L, 1.2%/1.2%, and 1.7 HU/1.6 HU.
Multivariable regression analysis showed that academic-based software tools had greater within-sub-
ject standard deviation of TLV than commercial vendors, but no significant differences between aca-
demic and commercial groups were found for LAA950 or Perc15 measurements.
Conclusions: Computed tomography total lung volume and lung density measurement bias and
reproducibility was reported across eight different software tools. Bias was negligible across vendors,
reproducibility was comparable for software tools generated by academic-based groups and commer-
cial vendors, and segmentation QA had negligible impact on measurement variability between soft-
ware tools. In summary, results from this study report the amount of additional measurement
variability that should be accounted for when using different software tools to measure lung density
longitudinally with well-standardized image acquisition protocols. However, intrasoftware repro-
ducibility was deterministic for all cases so use of the same software tool to reduce variability for
serial studies is highly recommended. © 2020 American Association of Physicists in Medicine
[https://doi.org/10.1002/mp.14130]
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1. INTRODUCTION
Computed tomography (CT) lung density is an imaging bio-
marker used to objectively and noninvasively quantify the
extent of emphysema in the lung. Over the last three decades,
numerous studies in patients with chronic obstructive pul-
monary disease (COPD) have demonstrated that CT lung
density measurements are correlated with emphysema mea-
sured in excised lungs by histology,2,3 are associated with
mortality5 and exacerbations,6 and can identify subgroups of
patients with better responses following lung-volume-reduc-
tion surgery7 and endobronchial valve implantation.8 Further-
more, in patients with alpha 1-antitrysin deficiency, a
significant response to augmentation therapy was shown
using CT lung density as a surrogate of emphysema, but not
with conventional spirometry measurements.9 These findings
all highlight the potential role of quantitative CT for COPD
patient management, such as longitudinal monitoring of dis-
ease progression and assessing treatment response.
Maintaining standardized image acquisition parameters,
however, is critically important for serial assessments that
aim to quantify CT lung density. It is well-established that
there are technical challenges for generating reproducible CT
measurements. Submaximal inspiration breath-hold vol-
ume,10 dose11,12 as well as image reconstruction parameters,
including slice thickness13,14 and reconstruction kernel,15–17
have all been shown to impact CT measurements. However,
several large, multicenter, longitudinal cohort studies, such as
COPDGeneTM,18 have utilized breath-hold coaching and ded-
icated lung phantoms to standardize image acquisition and
reconstruction parameters across all sites to minimize vari-
ability introduced by image acquisition related parameters.
Another factor that has the potential to impact the repro-
ducibility of CT measurements is the specific software used
to generate the measurements. Lung density measurements
are derived from the parenchymal density histogram of CT
Hounsfield unit (HU) values and thus are deterministic com-
putations and are directly computed given an accurate lung
segmentation mask.1–4 However, measurement variability
may be introduced by differences in the thoracic cavity seg-
mentation, as well as segmentation of the large airways and
pulmonary vessels, even when consistent image acquisition
and reconstruction settings are utilized. Previous studies
investigating the influence of different software tools have
shown conflicting results, and in some studies high intersoft-
ware variation for CT lung density measurements have been
reported.19–21
In an effort to standardize methodology, the Lung Density
Committee of the quantitative imaging biomarker alliance
(QIBA) has released for public comment a profile regarding
the CT lung density measurement.22 Given the multitude of
software tools used by different commercial, open-source,
and academic research laboratories, an evaluation of the inter-
software variability of CT lung density measurements is war-
ranted to support this profile, particularly in the context of
serial investigations. Furthermore, quantifying intersoftware
CT measurement reproducibility requires a cohort with
minimal variability introduced by image acquisition parame-
ters. Therefore, here our objective was to investigate and
report CT lung volume and lung density measurement inter-
software bias and reproducibility using CT images from the
COPDGeneTM cohort study, with various academic groups
and commercial vendors participating in the reproducibility
study.
2. MATERIALS AND METHODS
2.A. Details of the software comparison
Computed tomography images from 50 participants from
the COPDGeneTM cohort study18 were selected for analysis;
n = 10 participants across each COPD GOLD grade (GOLD
0–IV) were randomly selected. Participation was solicited
from academic groups and commercial vendors, and the
solicitation letter indicated that the results would be anon-
ymized (ie the software packages were provided on the condi-
tion they would not be individually identified). The
anonymization was performed by The Radiological Society
of North America (RSNA) that acted as a neutral broker
between all participating groups and the QIBA Lung Density
committee, to ensure that the committee was blinded to the
participants’ identity. The CT datasets used in this study are
accessible in the quantitative imaging data warehouse
(QIDW): https://qidw.rsna.org/.
All vendors indicated if their software tool was for aca-
demic use only or commercial. Vendors were instructed to
generate measurements: (a) without segmentation quality
assurance (QA) or manual correction to evaluate intersoft-
ware reproducibility; (b) a repeated set of measurements on
the same images, to evaluate intrasoftware reproducibility;
and, (c) a third set of measurements repeated on the same
images following segmentation QA and manual correction.
2.B. CT image acquisition
Computed tomography images were acquired using CT
systems of various makes and models, including GE, Sie-
mens and Philips models, with the participant supine at sus-
pended full-inspiration from apex to base of the lung as
previously described.18 In general, CT images were recon-
structed with smooth convolution kernels (Siemens B31f, GE
STANDARD, or Philips B) and slice thicknesses and inter-
vals between 0.625 and 0.75 mm. The full-dose protocol
used an effective dose of 200 mAs without dose modulation.
A more detailed description of the CT image acquisition pro-
tocol is described elsewhere.18
2.C. CT image analysis
Computed tomography images were processed using
academic and commercial CT lung density software. All
groups were instructed to generate CT measurements for
each image dataset using none or a minimal amount of
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manual software interaction. We also requested no image
auto-calibration or preprocessing (eg noise reduction filter-
ing). All vendors were asked to perform the following
steps for lung segmentation:
1. Segmentation of the lung parenchyma from the rest of
the thoracic cavity;
2. Removal of airways from the segmentation (no strict
definition of which airways were required to be
removed was provided, but the software was required
to at least remove the trachea and major bronchi from
the air-space prior to computing the CT lung density
metrics);
3. Blood vessel removal (no instruction was provided on
the amount of acceptable blood vessel exclusion from
the lung volume).
Next, groups were instructed to repeat each of these steps
on the same image dataset in order to assess the intrasoftware
repeatability. Finally, the vendors were asked to perform QA
by reviewing and manually correcting any lung segmentation
errors to generate a third set of CT measurements using the
corrected segmented lung volume.
The measurements generated include: the total lung vol-
ume (TLV), percentage of the low attenuation areas in the
lung with HU values below 950 (LAA950),1-3 and the HU
unit value corresponding to the 15th percentile on the
parenchymal density histogram (Perc15).4
2.D. Statistical analysis
All statistical analysis was performed using SAS 9.4
software (Cary, NC, USA) and MATLAB R2018a (Natick,
MA, USA). A one-way analysis of variance (ANOVA)
with a Tukey test for multiple comparison correction was
performed for statistical comparison between GOLD
groups for age; for sex and race, a Fisher’s Exact test was
used. MATLAB was used for Bland-Altman analysis to
compare measurements generated by each possible pair of
software tools; measurements include TLV, LAA950 and
Perc15 without QA. The reproducibility coefficient
(RDC)23 was calculated for each software tool, as
described below, to compare between the different soft-
ware tools for each lung measurement with and without
QA, and by group type (academic-based, commercial).
The RDC is the value under which the difference between
repeated measurements on the same participant acquired
under different conditions (ie. different software tools)
should fall within 95% probability. To estimate the RDC
for any given software tool, we must estimate the variance
relative to the other K  1 software tools in the compar-
ison (K = 8 in our study). Therefore, for a specific soft-
ware tool, l, we calculated the mean variance, r2l , for the
measurements, subscript i, across the 50 image sets, where
Mi;l represents measurement i of software l and r2i;k;l repre-
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The average RDC for software l is then given by:




Low RDC values indicate high reproducibility between
software tools. The 95% confidence intervals for the RDC
were constructed using bootstrapping with 5000 resamples.
Multivariable linear regression models were built to assess
whether group type (academic-based, commercial) was a pre-
dictor of the within-subject standard deviation of TLV,
LAA950 and Perc15 measurements. If group type was found
to be a significant predictor, it would indicate that the stan-
dard deviation between software tool measurements is differ-
ent for commercial vendors and academic groups; in other
words, it would indicate that CT measurements are more sim-
ilar between commercial vendors or academic groups. Gener-
alized estimating equations (GEEs) were used to account for
the clustered nature of the data.
3. RESULTS
A total of 50 participants were investigated: n = 10 in each
GOLD grade. As shown in Table I, there were no differences
between the groups for age, sex or race. A total of nine soft-
ware tools participated in the study; software tools 1–4 were
from academic-based groups and software tools 5–9 were
from commercial vendors. A single commercial vendor with-
drew from the study and therefore a total of eight software
tools, n = 4 research-based and n = 4 commercial, were
included in the analysis. All eight software tools were able to
generate measurements for all images provided. A total of
three of eight software tools reported some manual editing of
the segmentation masks for some of the CT images as part of
the QA step.
Figure 1 shows an example of the CT lung volume (in
blue) and LAA950 segmentation masks (in red) for two differ-
ent software tools. The differences observed for exclusion of
airways and vessels from the lung volume segmentation mask
between the two software tools are subtle and representative
of the type of differences that would be expected given
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acceptable segmentation quality for both images (i.e. no
major segmentation errors).
3.A. Bland-Altman analysis
Bland-Altman analysis was performed for TLV, LAA950,
and Perc15 measurements for each software tool compared
with all other software tools. Table II provides the summary
of the Bland-Altman analysis for measurements generated by
each software tool with the average of all the other software
tools for TLV, LAA950, and Perc15 measurements. There was
negligible bias for all software tools to within 0.22 L,
0.46%, and 0.97 HU, for TLV, LAA950, and Perc15
respectively.
3.B. Reproducibility coefficients
Table III shows the RDC for TLV, LAA950, and Perc15
measurements for eight different software tools with and
without QA using manual correction of the lung volume seg-
mentation. Overall, intersoftware RDC was 0.35 L, 1.2% and
1.8 HU for TLV, LAA950 and Perc15, respectively. Intersoft-
ware RDC remained unchanged following QA: 0.35 L, 1.2%
and 1.8 HU for TLV, LAA950 and Perc15 respectively. Intra-
software RDC was generated by performing repeated mea-
surements using the same software tool without QA; all
software had an intrasoftware RDC of 0, indicating that
image processing workflows were deterministic for all soft-
ware tools.












Age, yr 68 (8) 69 (9) 63 (10) 68 (9) 62 (6)
Female sex,
n (%)




10 (100) 9 (90) 8 (80) 8 (80) 6 (60)
African
American
0 (0) 1 (10) 2 (20) 2 (20) 4 (40)
aAll parameter values are mean (SD) unless otherwise noted.
FIG. 1. Computed tomography (CT) lung and emphysema segmentation gen-
erated by two different software tools. Shown above are two examples of CT
lung segmentation images from two different software tools. Areas of the
lung greater than or equal to  950 HU are colored in blue, areas
<950 HU are colored in red. Differences in the inclusion of blood vessels
(yellow arrows) and airways (white arrows) can impact lung volume and low-
attenuation area calculations. Note that the CT slice in this figure was the
slice with the largest disagreement in segmentation volume over the entire
image series. [Color figure can be viewed at wileyonlinelibrary.com]
TABLE II. Bland-Altman analysis for each software compared to the average












Software 1 0.15 0.14 0.05 0.06 0.25
Software 2 0.04 0.02 0.04 0.12 0.04
Software 3 0.22 0.23 0.05 0.32 0.13
Software 4 0.05 0.04 0.02 0.09 0.01
Software 5 0.04 0.04 0.03 0.01 0.09
Software 6 0.01 0.01 0.02 0.03 0.06
Software 7 0.21 0.19 0.05 0.10 0.31
Software 8 0.10 0.09 0.04 0.18 0.02
LAA950 (%)
Software 1 0.33 0.22 0.37 1.05 0.40
Software 2 0.24 0.18 0.28 0.31 0.80
Software 3 0.29 0.14 0.34 0.37 0.95
Software 4 0.42 0.39 0.29 0.15 0.98
Software 5 0.34 0.34 0.19 0.03 0.71
Software 6 0.42 0.39 0.20 0.82 0.02
Software 7 0.46 0.26 0.49 1.42 0.50
Software 8 0.09 0.10 0.12 0.32 0.15
Perc15 (HU)
Software 1 0.33 0.39 0.47 0.58 1.24
Software 2 0.20 0.14 0.36 0.90 0.51
Software 3 0.97 0.95 0.46 1.87 0.07
Software 4 0.49 0.54 0.39 1.25 0.27
Software 5 0.24 0.17 0.36 0.95 0.47
Software 6 0.88 0.80 0.27 0.35 1.40
Software 7 0.58 0.57 0.57 0.54 1.70
Software 8 0.11 0.18 0.32 0.52 0.74
TLV, total lung volume; Perc15, 15th percentile on the parenchymal density his-
togram.
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Table IV shows the RDC for TLV, LAA950, and Perc15
measurements for software tools by group type (academic or
commercial) with and without QA. Academic groups and
commercial vendor’s software tools generated comparable
RDC measurements for TLV, LAA950, and Perc15: 0.39 L/
0.32 L, 1.2%/1.2%, and 1.7 HU/1.6 HU respectively. As
shown in Table IV, QA had negligible impact on measure-
ment reproducibility between software.
3.C. Multivariable linear regression models
Table V shows multivariable linear regression models for
within-subject standard deviation of TLV, LAA950, and Per-
c15 measurements generated by the different software tools
with group type (academic, commercial) as a predictor. In the
multivariable linear regression model for within-subject stan-
dard deviation of TLV, group type (academic = 1, commer-
cial = 2) was a significant predictor (P < 0.0001); this
indicates that academic vendors had greater within-subject
standard deviation of TLV measurements than commercial
vendors. However, group type was not a significant predictor
for within-subject standard deviation in the multivariable lin-
ear regression model for LAA950 (P = 0.46) or Perc15 mea-
surements (P = 0.24).
4. DISCUSSION
There have been numerous clinical and research studies
demonstrating that quantitative CT lung density measure-
ments are related to important outcomes in COPD patients5-8
and in patients with alpha 1-antitrysin deficiency.9 Potential
clinical applications include patient selection for treatment
(eg by lung volume reduction surgery or endobronchial
valves), or for evaluating treatment response over time. How-
ever, in order for CT lung density measurements to be used
as a surrogate of emphysema in clinical applications, the vari-
ability of the CT measurements must be carefully controlled.
Several large, multicenter, longitudinal cohort studies, includ-
ing COPDGene,18 SPIROMICS,24 ECLIPSE,25 MESA26,
and CanCOLD,27 have implemented standardized image
acquisition protocols to carefully control for known factors
TABLE III. The reproducibility coefficient (RDC) for total lung volume
(TLV), LAA950 and 15th percentile on the parenchymal density histogram






RDC 95% CI RDC 95% CI
TLV (L)
Total 0.35 0.32–0.37 0.35 0.32–0.37
Software 1 0.38 0.35–0.41 0.38 0.35–0.42
Software 2 0.26 0.24–0.27 0.26 0.24–0.28
Software 3 0.26 0.24–0.29 0.26 0.24–0.29
Software 4 0.48 0.46–0.51 0.48 0.45–0.51
Software 5 0.25 0.23–0.27 0.25 0.23–0.27
Software 6 0.46 0.43–0.49 0.46 0.43–0.49
Software 7 0.31 0.28–0.34 0.31 0.28–0.34
Software 8 – – – –
Software 9 0.26 0.24–0.28 0.26 0.24–0.28
LAA950 (%)
Total 1.2 1.0–1.4 1.2 1.0–1.4
Software 1 1.2 1.0–1.5 1.2 1.0–1.5
Software 2 1.1 0.9–1.2 1.1 0.9–1.2
Software 3 1.1 0.9–1.2 1.1 0.9–1.2
Software 4 1.2 0.9–1.4 1.2 0.9–1.4
Software 5 1.2 1.0–1.3 1.2 1.0–1.3
Software 6 1.5 1.2–1.8 1.5 1.2–1.8
Software 7 0.9 0.7–1.0 0.9 0.7–1.0
Software 8 – – – –
Software 9 1.2 1.0–1.4 1.2 1.0–1.4
Perc15 (HU)
Total 1.8 1.6–2.0 1.8 1.6–2.1
Software 1 1.6 1.4–1.9 1.7 1.4–1.9
Software 2 1.5 1.3–1.7 1.6 1.3–1.8
Software 3 1.5 1.3–1.6 1.5 1.3–1.6
Software 4 2.3 2.1–2.6 2.3 2.1–2.6
Software 5 2.1 1.9–2.3 2.1 1.9–2.3
Software 6 2.0 1.6–2.3 2.0 1.6–2.4
Software 7 1.4 1.2–1.7 1.4 1.2–1.6
Software 8 – – – –
Software 9 1.7 1.5–1.9 1.7 1.5–1.9
TABLE IV. The reproducibility coefficient (RDC) for total lung volume
(TLV), LAA950 and 15th percentile on the parenchymal density histogram




without QA 95% CI
Intersoftware
RDC
with QA 95% CI
TLV (L)
Academic 0.39 0.36–0.41 0.39 0.36–0.41
Commercial 0.32 0.29–0.34 0.32 0.29–0.35
LAA950 (%)
Academic 1.2 0.9–1.4 1.2 0.9–1.4
Commercial 1.2 1.0–1.3 1.1 1.0–1.3
Perc15 (HU)
Academic 1.7 1.5–1.9 1.7 1.5–1.9
Commercial 1.6 1.3–1.9 1.6 1.3–2.0
TABLE V. Multivariable linear regression analysis for software tool type with
standard deviation of total lung volume (TLV), LAA950 and 15th percentile




TLV [SD] 0.03 0.004 <0.0001
LAA950 [SD] 0.009 0.01 0.46
Perc15 [SD] 0.04 0.03 0.24
Software type (academic = 1, commercial = 2).
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that impact CT measurements. However, the number of soft-
ware tools developed by academic groups and commercial
vendors to generate CT lung density measurements is
increasing, with several well-established commercial and pro-
totype software packages now available, and each has their
own proprietary segmentation algorithms. For serial assess-
ments or longitudinal evaluations where there is potential to
change software tools at different time-points the repro-
ducibility of CT measurements generated for various software
tools must be evaluated.
In this study, we evaluated reproducibility for eight differ-
ent software tools, including well-established software from
both academic groups and commercial vendors. We evaluated
participants without COPD and participants with a range of
COPD severities. Our results indicate relatively high repro-
ducibility across the different software tools for TLV,
LAA950, and Perc15 measurements. Although the Bland-Alt-
man analysis and Fig. 1 indicate that there are clear differ-
ences for total lung volume segmentation between some of
the vendors, which may result in the slight deviations
observed in the Bland-Altman analysis for LAA950, the bias
overall was quite low and for LAA950 the bias was less than
1% between all vendors. This bias is much less than reported
previously by Wielputz et al.20 who investigated five software
tools (two academic and three commercial) for lung density
measurements in COPD. The more reproducible findings
reported here may be related to several factors: the wider
range of severity of the patients investigated (the patients
evaluated by Wielputz et al.20 were mainly end-stage COPD);
the fact that a more standardized image acquisition protocol
was used for COPDGene; or potentially improvements in
image processing techniques over the last several years lead-
ing to more reproducible measurements between software
tools.
In addition to assessing intersoftware agreement for CT
measurements, we also generated RDC to determine how
much variability may be introduced by using different soft-
ware tools when repeated measurements are made on the
same patient. Again, although the measurements generated
by some software tools agreed slightly better than others, the
RDC values were low, and overall the RDC between all soft-
ware tools was only 1.2% for LAA950. For example, this indi-
cates that if the software tool was changed during a
longitudinal study, whereby there were repeated measure-
ments on the same patient but measurements were made
using different software, the variability attributed to the soft-
ware would be 1.2% for LAA950. In other words, to detect
real emphysema progression, the variability due to intersoft-
ware reproducibility measured in this study is 1.2% for
LAA950. However, to determine the true overall RDC, the
intersoftware reproducibility would need to be combined
with expected test/retest measurement repeatability arising
from differences in patient positioning, scanner model, scan-
ner calibration, breath hold volumes, etc., and a detection of
progression would need to be greater than the combined vari-
ability to be considered significant. Obuchowski et al.28 has
described the RDC calculations required to compute
measurement reproducibility and repeatability. In general,
however, we recommend that the same software be used for
sequential measures during a longitudinal study, especially
given that all methods showed deterministic intrasoftware
reproducibility.
Intrasoftware reproducibility was evaluated by having all
groups run their software tool on the same CT images a sec-
ond time. The RDC for the intrasoftware comparison was
zero. We also requested that each vendor run their software a
third time and perform more rigorous QA. Although three of
eight vendors reported that manual edits were required in
some of the participants evaluated (eg lung volume edits or
airway and vessel removal), the RDC did not change between
the first run when there was no QA and the third run when
QAwas performed. This finding suggests that the results gen-
erated between the software tools were similar regardless of
whether QA was performed. This may indicate that lung seg-
mentation and airway and vessel removal algorithms generate
similar results between vendors, before manual editing.
Finally, we investigated the RDC for CT measurements
stratified by whether the software was developed by aca-
demic-based groups or commercial vendors. Although
based on the RDC we found that the lung volume segmen-
tation results tended to agree slightly better within commer-
cial vendors than academic groups, the difference was very
small and the RDC for LAA950 was 1.2% for both com-
mercial and research vendors. This observation was consis-
tent with the results of the multivariable linear regression
analysis in which we investigated group type as a predictor
of the standard deviation between the CT measurements
generated by the different software tools. We found that
commercial vendors had lower within-subject standard devi-
ation of TLV than academic groups, but no difference was
found for LAA950 or Perc15 measurements. These findings
indicate that for CT lung density measurements, the repro-
ducibility within academic-based and commercial vendors
is similar.
Although efforts must be made to standardize CT mea-
surements, including image acquisition protocols and image
analysis software, there are other sources of variability that
may impact CT measurements that were not considered in
our study that must be acknowledged. For studies that acquire
multiple CT image series over a short period of time, there is
the potential for variability to be introduced due to physiolog-
ical or patient-related factors, but not disease related factors,
such as the patient orientation in the bore, slightly different
lung inflation volumes at breath-hold, etc. Previous studies
have investigated the short-term repeatability of CT lung den-
sity measurements within the same-day,29 over 2-weeks,30
and over a 1-yr period31 in healthy volunteers and COPD
patients. Although all studies report high short-term repeata-
bility for CT measurements, these patient related factors may
also impact how the software performs, and may add addi-
tional variability between groups. Therefore, an important
limitation in our study is that we did not investigate both the
reproducibility and short-term repeatability of the CT mea-
surements between software tools. Our study is also limited
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by the fact that assessment of CT lung segmentation accuracy
is ultimately subjective, and therefore we were only able to
compare measurement reproducibility between the various
software tools rather than accuracy, as ground truth segmen-
tation is not available. Another factor that should be consid-
ered is the potential for individual commercial or academic
groups to upgrade their software over time. For serial and
longitudinal studies, even when the same software tool is
used for CT analysis, CT measurement reproducibility may
need to be reassessed. Furthermore, we note that we did not
acquire CT measurements by lung lobe from software tools
and therefore we did not investigate CT measurement repro-
ducibility at the lobar level. Lobar segmentation algorithms
between software tools may be more variable than whole lung
segmentation. Reporting CT lung volume and density mea-
surements by lobe is relevant for lung volume reduction
applications, and therefore should be investigated in future
studies. We also acknowledge that instruction was provided
to the academic-based groups and commercial vendors using
their software tools for performing the analysis, including
how much manual intervention was permitted and that there
should be no preprocessing of the images. This may or may
not mimic how these vendors generate CT measurements rou-
tinely. However, the goal of our study was to assess the repro-
ducibility of their software for generating CT lung density
measurements under standardized conditions. Finally, as a
result of the well-standardized CT image acquisition parame-
ters used in this study, these findings may only be applicable
to other well-standardized studies, or to clinical trials. Further
investigation is required to determine CT measurement repro-
ducibility between software tools for studies involving a
wider range of CT acquisition parameters, such as those used
in clinical practice.
In conclusion, we evaluated CT lung volume and lung
density measurement reproducibility between eight different
software tools using CT images acquired with standardized
image acquisition protocols. The bias was negligible and
measurement reproducibility was high between software
tools, and was comparable for software developed by aca-
demic-based groups and commercial vendors. While using
the same software tool for serial studies is highly recom-
mended, these findings report how much added measurement
variability will be introduced should it be necessary to
include different software tools in serial studies with stan-
dardized image acquisition parameters, and provides guid-
ance on how to incorporate such information into
longitudinal studies.
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